{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:27:49Z","timestamp":1774438069469,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.dsx.2021.01.011","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T12:03:41Z","timestamp":1611317021000},"page":"385-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real world study of short term efficacy, safety, and tolerability of canagliflozin 100\u00a0mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8186-3697","authenticated-orcid":false,"given":"Debmalya","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dsx.2021.01.011_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/2230-8210.196016","article-title":"A\u00a0review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus","volume":"21","author":"Prasanna Kumar","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.dsx.2021.01.011_bib2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.dsx.2021.01.011_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.dsx.2021.01.011_bib4","first-page":"107","article-title":"Canagliflozin: a novel SGLT2 inhibitor for type 2 diabetes mellitus","volume":"6","author":"Kaushal","year":"2014","journal-title":"N\u00a0Am J Med Sci"},{"issue":"3","key":"10.1016\/j.dsx.2021.01.011_bib5","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.dsx.2021.01.011_bib6","first-page":"209","article-title":"Canagliflozin review - safety and efficacy profile in patients with T2DM","volume":"12","author":"Jakher","year":"2019","journal-title":"Diabetes MetabSyndrObes"},{"issue":"2","key":"10.1016\/j.dsx.2021.01.011_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/jod.jod_11_18","article-title":"Study on glycaemic control by canagliflozin and its effect on insulin resistance and plasma ketone in type 2 diabetes mellitus patients","volume":"10","author":"Kumar","year":"2019","journal-title":"Journal of Diabetology"},{"issue":"3","key":"10.1016\/j.dsx.2021.01.011_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/ijem.IJEM_55_19","article-title":"Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study","volume":"23","author":"Aneja","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dsx.2021.01.011_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2021.01.011_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jdiacomp.2014.12.016","article-title":"Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus","volume":"29","author":"Wilding","year":"2015","journal-title":"J\u00a0Diabet Complicat"},{"issue":"2","key":"10.1016\/j.dsx.2021.01.011_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/ijem.IJEM_578_17","article-title":"Characterization of metabolic parameters in responders and nonresponders treated with canagliflozin monotherapy in drug-naive subjects with type 2 diabetes","volume":"22","author":"Kutoh","year":"2018","journal-title":"Indian journal of endocrinology and metabolism"},{"issue":"1","key":"10.1016\/j.dsx.2021.01.011_bib12","doi-asserted-by":"crossref","first-page":"368-375","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.dsx.2021.01.011_bib15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.dsx.2021.01.011_bib16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.dsx.2021.01.011_bib17","article-title":"Canagliflozin-induced diabetic ketoacidosis: Case report and review of the literature","volume":"4","author":"Turner","year":"2016","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"issue":"5","key":"10.1016\/j.dsx.2021.01.011_bib18","doi-asserted-by":"crossref","first-page":"725-729","DOI":"10.4103\/2230-8210.183826","article-title":"Sodium-glucose cotransporter 2 inhibition and health benefits: the Robin Hood effect","volume":"20","author":"Kalra","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.dsx.2021.01.011_bib19","first-page":"40","article-title":"A\u00a0prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: real world evidence from clinical practice in India","volume":"64","author":"Sosale","year":"2016","journal-title":"J\u00a0Assoc Phys India"},{"issue":"9","key":"10.1016\/j.dsx.2021.01.011_bib20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ijcp.12868","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates","volume":"70","author":"John","year":"2016","journal-title":"Int J Clin Pract"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:12:50Z","timestamp":1761729170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402121000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1871402121000138"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2021.01.011","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world study of short term efficacy, safety, and tolerability of canagliflozin 100\u00a0mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2021.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}